This article was originally published in The Gray Sheet
Executive SummaryJohnson & Johnson subsidiary Cordis will enter the vascular closure device market in June with the European debut of its ExoSeal system. The bioabsorbable polyglycolic acid plug system, which is designed to close femoral artery puncture sites, received CE-mark approval in May. "An advantage compared to other devices is the procedural sheath does not need to be changed, which helps promote patient comfort," Cordis claims. Competing systems include Abbott's StarClose and St. Jude Medical's AngioSeal
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.